Focus on the discovery of next-generation LRRK2 inhibitors to unlock novel biological mechanisms of action and advance new treatment options ...

A mutation on a gene called LRRK2 is the most common genetic cause of Parkinson's Disease, which affects nearly 1 million Americans. While scientists have known that LRRK2 mutations are important ...

Arvinas' ARV-102 reduced LRRK2 protein in a Phase 1 trial, showing promising safety and pharmacodynamic outcomes for Parkinson's and PSP treatment.

Biotherapeutics Inc. has joined The Michael J. Fox Foundation for Parkinson’s Research (MJFF) LRRK2 Investigative Therapeutics Exchange (LITE) program.

Innovstone Therapeutics Ltd. has synthesized leucine-rich repeat kinase 2 (LRRK2; Dardarin) inhibitors reported to be useful for the treatment of Parkinson’s disease.

A first-in-human trial of Arvinas’ investigational Parkinson’s’ disease therapy, ARV-102, has been able to demonstrate a drop in the multifunctional protein that has been associated with the disease ...

NEU-411 is a brain-penetrant, potent and selective inhibitor of LRRK2 for the treatment of Parkinson’s disease (PD).

ARV-102 is Arvinas’ investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting leucine-rich repeat kinase 2 (LRRK2), a multifunctional protein that has been implicated in ...

Focus on the discovery of next-generation LRRK2 inhibitors to unlock novel biological mechanisms of action and advance new treatment options YONGIN, South Korea, April 15, 2025 – 1ST ...